Karami Hassan, Shirvani Shiri Maryam, Ebadi Fard Azar Farbod, Bagheri Lankarani Kamran, Ghahramani Sulmaz, Rezapour Aziz, Tatari Maryam, Heidari Javargi Zahra
Department of Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Front Med (Lausanne). 2023 Jan 19;9:1091330. doi: 10.3389/fmed.2022.1091330. eCollection 2022.
This was a 1-year prospective observational study of the health-related quality of life (HRQoL) of moderate to severe crohn's disease (CD) patients in Iran. Patients' HRQoL were measured using the EQ-5D 3L, EQ-VAS, and IBDQ-9 tools. HRQoL among CD patients were compared using the -test, Mann-Whitney, Chi-square, and Fisher's exact tests. To discover factors influencing patients' HRQoL, multivariate linear regression and multivariate logistic regression tests were utilized. The study included 222 CD patients, with a mean age of 34.67 and mean disease duration of 7.32 years. The dimensions with the worst reported "relatively or extreme problems" were P/D: 77.5% and A/D: 63.1%. Employment, having "other chronic diseases," and ADA consumption were the most important independent predictors of HRQoL in CD patients, [β = 0.21 (EQ-5D index), β = 19.61 (EQ-VAS), β = 12.26 (IBDQ-9), OR: 0.09 (MO), OR: 0.12 (UA), OR: 0.21 (P/D), OR: 0.22 (A/D)], [β = -0.15 (EQ-5D index), β = -5.84 (IBDQ-9), β = -11.06 (EQ-VAS), OR: 4.20 (MO), OR: 6.50 (UA)], and [OR: 2.29 (A/D)], respectively. Unemployment, presence of "other chronic conditions" had the greatest negative impact on HRQoL of CD patients. There were significant differences in the probability of reporting "relatively or extreme problems" in the SC and A/D dimensions between patients using adalimumab (ADA) and infliximab (IFX).
这是一项针对伊朗中重度克罗恩病（CD）患者健康相关生活质量（HRQoL）的为期1年的前瞻性观察研究。使用EQ-5D 3L、EQ-VAS和IBDQ-9工具测量患者的HRQoL。使用t检验、曼-惠特尼检验、卡方检验和费舍尔精确检验比较CD患者的HRQoL。为了发现影响患者HRQoL的因素，采用了多元线性回归和多元逻辑回归检验。该研究纳入了222例CD患者，平均年龄为34.67岁，平均病程为7.32年。报告“相对或极端问题”最严重的维度是P/D：77.5%和A/D：63.1%。就业、患有“其他慢性病”和使用阿达木单抗（ADA）是CD患者HRQoL最重要的独立预测因素，[β = 0.21（EQ-5D指数），β = 19.61（EQ-VAS），β = 12.26（IBDQ-9），OR：0.09（MO），OR：0.12（UA），OR：0.21（P/D）, OR：0.22（A/D）]，[β = -0.15（EQ-5D指数），β = -5.84（IBDQ-9），β = -11.06（EQ-VAS），OR：4.20（MO），OR：6.50（UA）]，以及[OR：2.29（A/D）]。失业、存在“其他慢性疾病”对CD患者的HRQoL有最大的负面影响。在使用阿达木单抗（ADA）和英夫利昔单抗（IFX）的患者中，SC和A/D维度报告“相对或极端问题”的概率存在显著差异。
